New drug ENX-104 tested for depression with anhedonia
NCT ID NCT07253324
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called ENX-104 in 48 adults with major depressive disorder who also experience anhedonia (loss of interest or pleasure). The main goal was to check the drug's safety and how the body processes it. The study is now complete, and results will help decide if further testing is warranted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MAC Clinical Research
Blackpool, Lancashire, FY2 0JH, United Kingdom
-
MAC Clinical Research
Prescot, Merseyside, L341BH, United Kingdom
-
MAC Clinical Research
Cannock, South Staffordshire, WS11 0BN, United Kingdom
-
MAC Clinical Research
Manchester, M13 9NQ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway ease teen depression?
- Can a nasal spray break through tough depression?
- Could a new drug offer hope for Treatment-Resistant depression?
- Targeting depression: can MRI-Guided brain zaps rewire key circuits?
- Can a psychedelic trip plus a gentle ear zap lift depression?
- Can a smart brain implant outsmart depression?